Daiwa Securities Group
ADMS

Daiwa Securities Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Daiwa Securities Group’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-142
Closed -$1K – 1265
2019
Q3 		$1K Hold
142
– – ﹤0.01% 1172
2019
Q2 		$1K Hold
142
– – ﹤0.01% 1196
2019
Q1 		$1K Hold
142
– – ﹤0.01% 1176
2018
Q4 		$1K Hold
142
– – ﹤0.01% 1137
2018
Q3 		$3K Hold
142
– – ﹤0.01% 1117
2018
Q2 		$4K Hold
142
– – ﹤0.01% 1113
2018
Q1 		$3K Buy
+142
New +$4.48K ﹤0.01% 1109

Other funds holding ADMS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Daiwa Securities Group's ADMS Position: Q4 2019 in Review

Daiwa Securities Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2019, closing a stake of 142 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in ADMS in Q1 2018 and held it in 7 quarters. The position peaked at $4K in Q2 2018. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

  • Daiwa Securities Group reported no remaining Adamas Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Daiwa Securities Group sold 142 Adamas Pharmaceuticals shares in Q4 2019, an estimated $1K.
  • Daiwa Securities Group first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 7 quarters.
  • Daiwa Securities Group's Adamas Pharmaceuticals position peaked at $4K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on Daiwa Securities Group's 13F filing for Q4 2019, filed 31 Jan 2020.